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Synthesis and biological evaluation of new
3-amino-2-azetidinone derivatives as anti-
colorectal cancer agents†
Farida Tripodi, a Federico Dapiaggi, b Fulvia Orsini, b Roberto Pagliarin, *b
Guido Sello *b and Paola Coccetti *a
Several synthetic combretastatin A4 (CA-4) derivatives were recently prepared to increase the drug efficacy
and stability of the natural product isolated from the South African tree Combretum caffrum. A group of
ten 3-amino-2-azetidinone derivatives, as combretastatin A4 analogues, was selected through docking ex-
periments, synthesized and tested for their anti-proliferative activity against the colon cancer SW48 cell
line. These molecules, through the formation of amide bonds in position 3, allow the synthesis of various
derivatives that can modulate the activity with great resistance to hydrolytic conditions. The cyclization to
obtain the 3-aminoazetidinone ring is highly diastereoselective and provides a trans biologically active iso-
mer under mild reaction conditions with better yields than the 3-hydroxy-2-azetidinone synthesis. All com-
pounds showed IC50 values ranging between 14.0 and 564.2 nM, and the most active compound showed
inhibitory activity against tubulin polymerization in vitro, being a potential therapeutic agent against colon
cancer.
Introduction
Combretastatins are a group of polyhydroxylated stilbenes iso-
lated from the South African tree Combretum caffrum.1,2 They
are natural-occurring well-known microtubule destabilizing
agents that inhibit the polymerization of tubulin by binding
to its colchicine binding site. Combretastatin A4 (CA-4,
Fig. 1), the main component of this family of natural prod-
ucts, is in advanced clinical trials for cancer therapy because
it exhibits potent anticancer activity against a panel of human
cancer cells including multi-drug resistant ones.3
CA-4 has anti-angiogenic effects inducing apoptosis in var-
ious human tumor cell lines,4–7 through blocking of the
blood flow, vascular rupture and cellular necrosis. Two prob-
lems, however, have limited their use as therapeutic agents
for a long time: low water solubility and cis/trans CC double
bond isomerization, which may occur during storage and ad-
ministration, causing a dramatic loss of activity. Between the
two stereoisomers, the cis form is much more active than the
trans one, due to the pharmacophore of the colchicine bind-
ing site, which encompasses the trimethoxybenzene ring in
cis linked to a methoxy-containing arene.8 The low solubility
has been overcome by a water-soluble phosphate prodrug9
(Fig. 1), which is currently under investigation in human clin-
ical trials (phase III) as an anticancer drug.4,9,10 The low cis
isomer stability has been approached by designing a variety
of conformationally restricted cis-locked analogues. Many
structural modifications of combretastatin A4 have been pro-
posed by incorporating the stilbene double bond into a car-
bocyclic or heterocyclic moiety. Carbocyclic derivatives,
containing a phenyl ring, or a triatomic or a pentaatomic
ring, have to be cited, as well as nitrogen or oxygen-containing
heterocyclics,11 triazoles,12 tetrazoles,13 isooxazoles,14 imidazoles,15
pyrazoles,16 and pyridines.17 Other rings, such as azetidinones,
have been inserted between the two phenyl groups of
combretastatin A4.18,19 In addition, trans-3,4-disubstituted
azetidinones show strong anti-proliferative activity against several
cancer cell lines.20,21 Combretastatin-like compounds bearing an
azetidinone unit between the A and B rings were presented by N.
M. O'Boyle and colleagues.22,23 They firstly synthesized a few
Med. Chem. Commun., 2018, 9, 843–852 | 843This journal is © The Royal Society of Chemistry 2018
aDepartment of Biotechnology and Biosciences, University of Milano-Bicocca,
Milan, Italy. E-mail: paola.coccetti@unimib.it
b Department of Chemistry, University of Milano, Milano, Italy.
E-mail: roberto.pagliarin@unimi.it, guido.sello@unimi.it
† Electronic supplementary information (ESI) available. See DOI: 10.1039/
c8md00147b
Fig. 1 The main component of combretastatins: combretastatin A4
and its phosphate derivative.
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derivatives of trans 1,3,4 tri-aryl azetidinone 1 (Fig. 2) which
inhibited the polymerization of tubulin with a 6-fold rate of inhibi-
tion in comparison with the natural compound CA-4.22,23
We recently developed a trans-3-hydroxy-2-azetidinone, bear-
ing in position 1 the A ring and in position 4 the B ring of CA-4
(compound 2) (Fig. 3).24 The racemic mixture of this compound
showed both high stability and solubility (1700 μM) in aqueous
media due to the presence of a second hydroxyl group in posi-
tion 3. It was synthetized under thermodynamic control of the
reaction at 100 °C with a total yield of 33%. Compound 2 in-
duced inhibition of tubulin polymerization and subsequent
G2/M arrest in cancer cells.24 At the same time, activation of
AMP-activated protein kinase (AMPK) and induction of apopto-
sis were also reported.24 Moreover, the drug displayed signifi-
cant nanomolar cytotoxic activity against different cancer cell
lines, as well as a tumor growth delay in a colorectal cancer
mouse xenograft model, confirming its potential therapeutic
action against colon cancer.25 In the present paper, we report
the synthesis of compound 3 (Fig. 3), in which the hydroxyl
group of compound 2 was substituted by an amino group, as
well as a series of its derivatives. Remarkably, the synthesis of
compound 3 was easier than that of compound 2 because in
the Staudinger reaction, the trans closure of the azetidinone
ring took place at room temperature with an overall yield of
50%, with only a few traces of the cis isomer.
In order to select derivatives of compound 3 which could
have pronounced activity, we performed a preliminary
docking study before biological tests. The presence of the
amino group permits the easy preparation of a series of deriv-
atives by transforming NH2 to its corresponding amido
group. The variability in size and functions of the introduced
substituents can be the source of valuable insights into sub-
strate binding site interactions.
We hypothesized the preparation of 10 derivatives (com-
pounds 11a–j) (Table 1), where the R residue derived from
the acidic part of the amido group varies from acetic to
naphthoic acids. We included short chain, aromatic, hetero-
aromatic, cyclic and polycyclic derivatives with diverse func-
tional groups.
First, we examined the docking of compounds 2a and 2b
showing anticancer activity in previous studies (Fig. 4).24 Mo-
lecular docking was performed generating 100 binding poses
for each compound. Considering the similarity of the ener-
gies obtained from the molecular docking of these com-
pounds (Tables S1 and S2†), we performed a cluster analysis
on the 100 conformations obtained from each run using an
RMSD threshold of 2 Å. We considered the most populated
cluster of each compound as the best docked conformation.
Compound 2a (enantiomer SS) showed the known interaction
of the trimethoxyphenyl group that came into contact with
Cysβ241 and Valβ238. In addition, it interacted with Aspβ251
through hydrogen bonds. Compound 2b (enantiomer RR)
maintained the interaction of the trimethoxyphenyl group
with Cysβ241 and Valβ238. In contrast, it did not interact
with Aspβ251, suggesting that the two enantiomers did not
share the same docking conformation.
Then, molecular docking studies were carried out on com-
pounds 11a–j in order to assess their ability to bind to the
colchicine site of β tubulin.
RR enantiomers showed low binding capability, displaying
a large number of clusters of different conformations. Com-
pound 11i resulted to be the most interesting compound
among the RR enantiomers, displaying a very populated clus-
ter containing 85% of the conformations. Details regarding
binding energies and clustering are reported in Table S1.†
Much more interesting results were obtained from the mo-
lecular docking of SS enantiomers. In this case, most of the
docked compounds showed a more highly populated cluster
with respect to RR compounds and binding energies around
−5 kcal mol−1 (Table S2†). Compounds 11d, 11f and 11g were
not suitable to bind within the colchicine site, due to the ste-
ric hindrance of the R substituents of the amide group. This
was supported by highly diversified docked conformations.
Compounds 11a, 11b, 11c, 11e, 11h and 11j shared the same
orientation within the binding site (Fig. 5). Like
combretastatin compounds,8 the trimethoxyphenyl group
came into contact with Cysβ241 and Valβ238. Moreover, the
amidic group in position 3 interacted with Metβ259 through
a hydrogen bond (Fig. 6). The most interesting compound,
however, was 11i, showing a single cluster of 100
conformations.
This compound showed a different docking pose with re-
spect to the aforementioned ones. It interacted with Asnα101
and Aspβ251 through hydrogen bonds, while the orientation
of the trimethoxyphenyl group was towards residues Cysβ241
and Valβ238 as in the previous cases (Fig. 7). Moreover, com-
pound 11i showed a very similar docking pose to compounds
already studied by our group, namely trans 3-hydroxy-1,4-
diaryl-2-azetidinone (2b) (Fig. 8).
Fig. 2 Triaryl derivatives of azetidinone proposed by O'Boyle and
coworkers.22
Fig. 3 Azetidinone derivatives proposed by Tripodi and coworkers.24
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In keeping with these results, the syntheses of all the de-
rivatives were performed.
Chemistry
In this work, we focused our attention on the preparation of
a small library of 3-amido-1,4-diaryl-2-azetidinones 11a–j
(Table 1), with the goal of improving the biological activity
and elucidating the biological effects by the introduction of
specific ligands useful to selectively target tumor cells.
3,4-trans-3-Amino-4-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-tri-
methoxyphenyl)-azetidin-2-one 9 was synthesized as previously
reported by the authors,24 via the Staudinger approach be-
tween a properly selected imine 6 and phthalylglycyl chloride
as the ketene precursor, followed by hydrolysis with hydra-
zine dihydrochloride at 60 °C (Scheme 1). The stereochemistry
of the products obtained from the Staudinger cycloaddition
was affected by the experimental conditions (such as solvent,
temperature and order of addition of the reagents) and by the
type of the ketene precursor: acetoxyacetyl chloride or
phthalylglycyl chloride, used to introduce an OH group or a
NH2 group, respectively, at the position 3 of the azetidin-2-one.
In the latter case, the best results were obtained by dropwise
addition of a 4-fold excess of acid chloride 7 to a methylene
chloride solution of imine 6 and dry triethylamine at 0 °C,
followed by stirring at room temperature for twenty-four
Table 1 Structures and IC50 values of the indicated compounds in SW48 cell lines measured by the MTT assay after 72 h of treatment (0.1% DMSO was
used as a vehicle control)
Entry Compound IC50 (nM) Entry Compound IC50 (nM)
11a 270.7 ± 76.6 11f 220.2 ± 76.5
11b 384.2 ± 117.3 11g 49.4 ± 1.1
11c 108.4 ± 11.6 11h 244.2 ± 64.2
11d 564.2 ± 61.7 11i 14.0 ± 2.1
11e 18.6 ± 1.7 11j 90.6 ± 7.3
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hours. Hydrolysis of the Staudinger adduct with hydrazine
afforded only trans-diastereoisomer 9 in 61% total yield from
the imine. A different approach,26 based on the use of in situ
generated N-chloramines as imine precursors, was tested,
without improving the yields of the reaction.
With respect to previously reported 3-hydroxy-1,4-diaryl-2-
azetidinones, 3-amino-1,4-diaryl-2-azetidinones could a priori
display different and hopefully improved activity, and the ni-
trogen atom at position 3 can be derivatized to give stable
amides, easily prepared by reaction with a properly selected
carboxylic acid, RCOOH. In order to obtain a library of com-
pounds able to interact with the receptors in a variety of
ways, R has been varied in terms of polarity, size, and ability
to act as a hydrogen bond acceptor or donor and to give dif-
ferent types of interactions, namely dipole–dipole, β-stacking
and hydrophobic interactions.
Amides 11a–i were obtained by a five-step synthesis. As al-
ready described,24 imine 6 was obtained by reaction of com-
pounds 4 and 5 in anhydrous ethyl alcohol: the solid com-
pound 6 was subjected to Staudinger cyclization with
phthalyl glycine chloride and was transformed into β-lactam
8, which was easily hydrolyzed to compound 9. 3,4-trans-3-
Amino-4-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxy-
phenyl)-azetidin-2-one 9 was first added to an acetonitrile so-
lution of the selected carboxylic acid, previously activated by
reaction with N,N′-disuccinimidyl carbonate (overnight at
room temperature). A mixture of the N,O-diacyl derivative 10
and amide 11 was obtained. Pure samples of 11a–j were
obtained by flash-chromatography, whereas, the presence of
N,O-diacyl derivatives 10a–j was recognized in the MS spectra
of the mixtures (10a–j and 11a–j) which were directly treated
with hydrazine hydrochloride at room temperature to hydro-
lyse the ester moiety. The target amides 11a–j were thus
obtained with total yields ranging from 60% to 81%
depending on the R substituents of the amide group. The
synthesis of the amide 11j required one additional step as
tert-butoxycarbonyl alanine was used as an acylating reagent:
the removal of the protective tert-butoxycarbonyl moiety was
easily accomplished by treatment with trifluoroacetic acid in
methylene chloride.
Biological results
Compounds 11a–j were tested against the SW48 human colon
cancer cell line by testing their antiproliferative activity. They
retained their nanomolar cytotoxic activity, and among them
11i, with a small alkyl group (methyl), showed the highest ac-
tivity, comparable to the activity of natural CA-4 and of the
previously reported 3-hydroxy azetidinone 2 (Table 1, Fig.
S1†). The activity was decreased by the introduction of a pri-
mary amino group on the small alkyl chain in 11j and, even
more, by the substitution of the methyl group with the more
Fig. 4 SS an RR enantiomers of compound 2, previously tested as
anticancer agents.
Fig. 5 Superimposition of docking poses of compounds 11a (blue),
11b (red), 11c (orange), 11e (yellow), 11h (green), and 11j (purple).
Fig. 6 Interactions of the compound 11a. In the illustration, tubulin α
(orange) and β (cyan) subunits are represented. Trimethoxyphenyl
group came into contact with residues Cysβ241 and Valβ238, as well
as HB with residue Metβ259. This interaction pattern was common to
compounds 11a, 11b, 11c, 11e, 11h, and 11j.
Fig. 7 Interactions of compound 11i. In the illustration, tubulin α
(orange) and β (cyan) subunits were represented. Trimethoxyphenyl
group is in contact with residues Cysβ241 and Valβ238. Moreover, two
hydrogen bonds were observed between the amide group in position
3 and Asnα101 as well as between the ketone oxygen of the scaffold
and Aspβ251. This interaction pattern was common to compounds 11i
and 2b.
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sterically demanding cyclohexyl group in 11h. Hetero-
aromatic rings, as in 11e and 11g, were approximately compa-
rable to that in 11i. In the presence of aromatic rings, as in
11a–11d, the activity was further reduced. The results of the
activity tests were consistent with the assessments from the
docking study, where the compounds containing bulky aro-
matic residues did not converge to a single structure.
CA-4 is known to act by inhibiting tubulin polymeriza-
tion.1 Thus, we evaluated the effect of compound 11i, which
showed the highest activity against SW48 cells, on the in vitro
polymerization of purified tubulin, and CA-4 was used as a
positive control (Table 2, Fig. S2†). In the assembly assay, 11i
showed an IC50 value of 5.05 μM, higher than that of CA-4,
but indicative of the fact that one of the molecular targets of
this active compound was tubulin, as reported for other
azetidinone compounds.24
Conclusions
Insertions of azetidinone rings into the combretastatin skele-
ton have been valid modifications because they prevented the
isomerization of the cis double bond, while preserving the ac-
tivity of some derivatives comparable to that of the natural
compound. They made the natural compound more stable
and the synthesis provided good yields. In particular, the
3-aminoazetidinones, compared to the 3-hydroxyazetidinones,
which bear a hydroxyl group in position 3 of the β-lactam
ring, were synthesized with higher yields since the Staudinger
reaction almost exclusively provided the 3,4-trans isomer. Fur-
thermore, the derivatization of the amino group afforded am-
ide derivatives which were stable under hydrolytic conditions.
Remarkably, these new derivatives showed nanomolar anti-
proliferative activity against SW48 cells, probably acting by
inhibiting tubulin polymerization, opening the route to a
new class of potential therapeutic agents against colon
cancer.
Experimental section
Docking studies
The tubulin X-ray structure in a complex with combretastatin
was obtained from the protein data bank (PDB ID 5LYJ8). The
pocket analysis and the docking calculations were performed
only on one of the dimers in the asymmetric unit, labelled
chains A and B. Combretastatin was removed from the struc-
ture before docking our compounds. Docking was carried out
with Autodock 4.2,27 employing a Lamarckian genetic algo-
rithm.28 100 independent runs per molecule were performed.
In each run, a population of 50 individuals evolved along
27 000 generations and a maximum number of 25 million en-
ergy evaluations were performed. The best fit (lowest docked
energy) solutions of the 100 independent runs were stored
for subsequent analysis. The visual inspection of docked
structures was carried out using VMD.29
Chemistry
All commercially available reagents were purchased from
Sigma-Aldrich and used without further purification. Prepara-
tive separations were usually performed by flash-column
chromatography on silica gel (Merck grade 9385). Thin-layer
chromatography was conducted on silica gel (Merck, 10 × 5
cm, silica gel 60 F254): zones were detected visually by ultra-
violet irradiation (254 nm) or by exposition to iodine vapors.
1H NMR and 13C NMR spectra were recorded at 300 MHz and
400 MHz on Bruker instruments (AC 300 UltrashieldTM 400),
using deuterochloroform solutions, unless otherwise speci-
fied, and chemical shifts were represented as δ-values relative
to the internal standard TMS. ESI-mass spectra were recorded
on a Bruker Esquire 3000 Plus. The synthesized compounds
subjected to biological tests have a purity of ≥95% deter-
mined by HPLC (Phenomenex, Nucleosil 250 × 3.2 mm col-
umn, 5 μm, C18; mobile phase 0.05 M phosphate buffer pH
7/acetonitrile, 7 : 3; flow rate 1.5 mL min−1), and they have
been filtered in sterile atmosphere with 0.20 μm filters.
3-Hydroxy-4-methoxybenzylidene-(3,4,5-trimethoxyphenyl)-
amine (6). Under an inert atmosphere, compound 4 (1.9, 10.1
mmol) and compound 5 (1.5 g, 10.1 mmol) were dissolved to-
gether at room temperature with stirring, in 10 mL ethanol
previously dried on molecular sieves. The reaction was
followed by TLC (pre-treatment of the plate with CH2Cl2 :
Et3N 95 : 5, then eluted with AcOEt : Esano 1 : 1). After 2 h,
NMR analysis showed the formation of imine 6 which was
observable also by the presence of a precipitate. The mixture
was filtered to collect the solid product. The filter was
washed twice with dichloromethane to dissolve the reaction
product. The solvent was removed and compound 6 was col-
lected, pure enough for the next step (yields = 93%). 1H-NMR
(CDCl3): δ 8.41 (1H, s), 7.63 (1H, s), 7.46 (1H, d, J = 7.2 Hz),
6.96 (1H, d, J = 7.2 Hz), 6.53 (2H, s), 5.77 (1H, s), 3.99 (3H, s),
3.92 (6H, s), 3.88 (3H, s). EI-MS (m/z): 318 (M+).
(±)-3,4-trans-3-Amino-4-(3-hydroxy-4-methoxyphenyl)-1-
(3,4,5-trimethoxyphenyl)-azetidin-2-one ((±)-trans-9). A solu-
tion of phthalylglycyl chloride (5.38 g, 24 mmol), in anhy-
drous methylene chloride (7 mL), was added dropwise at 0 °C
under nitrogen to a stirred solution of imine 6 (1.9 g, 6
mmol) and TEA (8.3 mL, 60 mmol) in anhydrous methylene
chloride (7 mL). The solution was maintained at 0 °C for 1 h
and then allowed to reach room temperature and stirred for
Fig. 8 Superimposition of 11i (blue) and 2a (red) docking poses.
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24 h. HCl (1 N) was added (40 mL), and the two phases were
stirred for 40 min. The aqueous phase was separated and
extracted twice with dichloromethane. Organic phases were
washed with a saturated solution of NaHCO3, dried with so-
dium sulfate, filtered, and concentrated under reduced pres-
sure, affording a brown oil which was purified by flash col-
umn chromatography (silica gel; eluent gradient of n-hexane/
ethyl acetate from 7/3 to 4/6). The isomer (±)-trans-8 only was
isolated with a 65% yield. The isomer (±)-cis-8 was formed
only in traces from the reaction. (±)-trans-8: 1H-NMR (CDCl3)
δ 8–7.6 (8H, m), 7.29 (1H, dd, J1 = 8.4 Hz, J2 = 2.2 Hz), 7.19
(1H, d, J = 2.2 Hz), 7.00 (1H, d, J = 8.4 Hz), 6.57 (2H, s), 5.28
(2H, s), 4.71 (2H, s), 3.85 (3H, s), 3.76 (3H, s), 3.70 (6H, s).
13C NMR (CDCl3): δ 167.46, 166.96, 165.41, 162.03, 140.09,
134.79, 134.53, 133.40, 132.15, 131.86, 128.37, 126.40, 125.08,
124.27, 123.87, 121.47, 113.64, 95.50, 67.78, 61.07, 56.24,
38.89. ESI-MS: m/z 691 (M+).
Hydrazine dihydrochloride (752.5 mg, 6.223 mmol) was
added, at 0 °C and under nitrogen, to a stirred suspension of
(±)-trans-8 (870 mg, 1.245 mmol) in methanol (10 mL). TEA
(3.5 mL, 24.89 mmol) was then added dropwise. The mixture
was allowed to reach room temperature and then warmed at 50
°C for 5 h. The solvent was removed at reduced pressure, and
the residue was treated with 1 N HCl (40 mL) and extracted with
dichloromethane (3 × 10 mL). The aqueous phase was made al-
kaline by 3 N NaOH and extracted with dichloromethane (3 × 10
mL). The organic phase was dried (Na2SO4), and the solvent was
removed at reduced pressure. A solid was obtained, which was
purified by flash chromatography (silica gel; eluent n-hexane/
ethyl acetate, 2/8) to afford the stereoisomer (±)-trans-9 (0.437 g,
1.17 mmol, 94% yield) as a yellow solid. 1H-NMR (CDCl3): δ 6.92
(1H, s), 6.89 (2H, s), 6.54 (2H, s), 4.54 (1H, d, J = 2.2 Hz), 4.05
(1H, d, J = 2.2 Hz), 3.88 (3H, s), 3.76 (3H, s), 3.71 (6H, s). 13C
NMR (CDCl3): δ 168.05, 153.65, 147.11, 146.51, 134.80, 133.80,
Scheme 1 Reagents and conditions: a) anhydrous EtOH; b) Et3N/CH2Cl2; c) NH2NH2·2HCl, Et3N, MeOH, 60 °C; d) N,N′-disuccinimidyl carbonate,
Et3N, CH3CN; e) NH2NH2·2HCl, Et3N, MeOH, r.t.
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130.14, 118.14, 117.99, 112.33, 111.22, 95.38, 69.70, 66.70, 61.09,
56.22. ESI-MS: m/z 374 (M+).
General procedure for the preparation of compounds
11a–h and 11j. To a stirred solution of the selected carboxylic
acid RCOOH (0.88 mmol) in dry acetonitrile (6 mL), N,N′-
disuccinimidyl carbonate DSC (0.88 mmol) and dry triethyl-
amine (1.603 mmol) were added at 0 °C, under a nitrogen at-
mosphere. The stirring was continued overnight and 3,4-
trans-3-amino-4-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-tri-
methoxyphenyl)-azetidin-2-one 9 (0.4 mmol) was added. The
reaction was monitored by TLC (silica gel, eluted with methy-
lene chloride–methanol), treated with a saturated solution of
NaHCO3, and extracted with methylene chloride. The com-
bined organic extracts were dried (Na2SO4) and the solvent
was removed under reduced pressure. A mixture of 11a–i and
10a–i in varying amounts was obtained (the latter generally
detected in the MS and/or NMR spectrum of the crude mate-
rial) and directly hydrolyzed to 11a–i.
When Boc-N-methyl-L-alanine was used as an acyl donor, a
mixture of Boc-protected N-acylated and N,O-di-acylated deriv-
atives was obtained, directly hydrolyzed to the protected Boc-
N-acyl derivative and deprotected with trifluoroacetic acid to
afford 11j.
Hydrolysis of the ester group was achieved by addition
of hydrazine dichloride (0.174 mmol) and dry triethyl
amine (0.34 mmol) to a stirred solution of the mixture of
10a–j and 11a–j (0.087 mmol) in methanol (4 mL), under a
nitrogen atmosphere. The reaction was monitored by TLC
analysis (silica-gel). The reaction was then treated with
KHSO4 solution (5%) and extracted with methylene chlo-
ride. The combined organic extracts were dried and the sol-
vent was removed under reduced pressure. The crude mate-
rial was flash chromatographed on silica gel, eluting with a
gradient of methylene chloride–methanol affording pure
11a–j.
N,O-(Diacetyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one (10i).
The title compound was prepared as well by addition of
acetic anhydride (2 mL) to 3,4-trans-3-amino-4-(3-hydroxy-4-
methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-azetidin-2-one 1.
Removal of acetic anhydride under reduced pressure afforded
the diacyl derivative in quantitative yields.
10i 1H NMR (300 MHz, CDCl3): δ ppm 7.19 (dd, 1H, J =
8.5, 1.7 Hz), 7.05 (d, 1H, J = 1.7 Hz), 6.95 (d, 1H, J = 8.5
Hz), 6.80 (d, 1H, J = 7.5 Hz), 6.48 (s, 2H), 4.94 (d, 1H, J =
1.7 Hz), 4.53 (dd, 1H, J = 7.4, 1.7 Hz), 3.81 (s, 3H), 3.75 (s,
3H), 3.69 (s, 6H), 2.28 (s, 3H), 2.06 (s, 3H). 13C (300 MHz,
CDCl3): 171.45, 169.45, 164.88, 154.08, 152.16, 140.84,
135.12, 134.10, 129.46, 125.23, 121.82, 113.64, 95.73, 66.55,
63.27, 61.57, 56.67, 23.35, 21.25. MS (ESI): m/z 481 (M +
Na).
Spectroscopic data of compounds 11a–j
N-(4-Chlorobenzoil)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11a
(65% yield). 1H NMR (400 MHz, CDCl3): δ ppm 7.79 (d, 2H, J
= 7.5 Hz), 7.43 (d, 2H, J = 7.5 Hz), 7.23 (d, 1H, J = 6.5 Hz,
NH), 6.98 (d, 1H, J = 2.5 Hz), 6.94 (dd, 1H, J = 7.5, 2.5 Hz),
6.88 (d, 1H, J = 7.5 Hz), 6.55 (s, 2H), 5.00 (d, 1H, J = 2.0 Hz),
4.81 (dd, 1H, J = 7.5 Hz, 2.0 Hz), 3.92 (s, 3H), 3.77 (s, 3H),
3.72 (s, 6H). 13C (400 MHz, CDCl3): 168.13, 165.29, 154.31,
147.43, 146.57, 136.15, 135.06, 130.76, 130.86, 129.90, 129.15,
118.92, 116.33, 116.14, 112.57, 111.63, 95.72, 66.83, 63.93,
61.51, 56.25, 56.13, 51.44. MS (ESI): m/z 535–537 (M + Na).
10a. MS (ESI): m/z 673–675 (M + Na).
N-(4-Fluorobenzoyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11b
(66% yield). 1H NMR (400 MHz, CDCl3): δ ppm 7.90 (dd, 2H,
J = 8.5, JH–F = 5.5 Hz), 7.82 (d, 1H, J = 7.4 Hz, NH), 7.08 (dd,
2H, J = 8.5, JH–F = 8.4 Hz), 6.95 (d, 1 H, J = 1.5 Hz), 6.90 (dd,
1H, J = 8.1, 1.5 Hz), 6.84 (d, 1H, J = 8.1 Hz), 6.52 (s, 2H), 5.01
(s, 1H), 4.85 (d, 1 H, J = 7.4 Hz), 3.89 (s, 3H), 3.74 (s, 3H),
3.68 (s, 6H).13C (400 MHz, CDCl3): 168.05, 166.71 (JC–F = 253
Hz), 165.44, 154.95, 148.63, 147.87, 135.97, 134.87, 131.31
(JC–F = 9.1 Hz), 130.77, 130.44, 120.70, 116.98 (JC–F = 21.9 Hz),
113.55, 112.41, 95.82, 66.73, 63.73, 61.58, 56.65, 56.64, 51.45.
MS (ESI): m/z 519 (M + Na). 10b. MS (ESI): m/z 641 (M + Na).
N-(4-Methoxybenzoyl)-3,4-trans-3-amino-1-(3,4,5-tri-
methoxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-
one. 11c (64% yield). 1H NMR (400 MHz, CDCl3): δ ppm 7.82
(d, 2H, J = 7.6 Hz), 6.98 (s, 1H), 6.93 (dd, 1H, J1 = 7.5 Hz),
6.86 (d, 1H, J = 7.5 Hz), 6.56 (s, 2H), 5.25 (s, 1H), 4.79 (d, 1H,
J = 6.4 Hz), 5.85 (d, 1H, J = 6.4 Hz, NH), 3.89 (s, 3H), 3.87 (s,
3H), 3.77 (s, 3H), 3.70 (s, 6H). 13C (300 MHz, CDCl3): δ ppm
167.38, 164.82, 162.61, 153.34, 147.27, 146.37, 134.54, 133.43,
129.88, 129.2, 125.04, 118.17, 113.78, 112.49, 111.19, 95.24,
66.2, 63.17 60.88, 60.03, 55.95, 55.38, 50.55. MS (ESI): m/z 531
(M + Na).
10c. MS (ESI): m/z 665 (M + Na).
N-(3,4,5-Trimethoxybenzoyl)-3,4-trans-3-amino-1-(3,4,5-tri-
methoxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-
one. 11d (60% yield). 1H NMR (400 MHz, CDCl3): δ ppm 8.34
(d, 1H, J = 6.5 Hz), 7.11 (s, 2H), 6.87 (d, 1H, J 0 1.0 Hz), 6.82
(dd, 1H, J = 8.8, 1.0 Hz), 6.78 (d, 1H, J = 8.8 Hz), 6.50 (s, 2H),
5.02 (d, 1H, J = 2.2 Hz), 4.71 (dd, 1H, J = 6.5), 3. 82 (s, 3H), 3.
81 (s, 3H), 3.80 (s, 6H), 3.73 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H).
13C (300 MHz, CDCl3): δ ppm 167.87, 165.82, 154.07, 153.99,
152.34, 148.09, 147.21, 135.08, 134.22, 129.99, 129.74, 128.58,
124.45, 118.75, 113.14, 111.94, 108.12, 105.47, 95.74, 93.33,
66.88, 63.34, 61.55, 56.77, 56.67, 56.70, 51.00. MS (ESI): m/z
591 (M + Na).
10d. MS (ESI): m/z 785 (M + Na).
N-(2-Furoyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxyphenyl)-
4-(3-hydroxy-4-methoxiphenyl)-azetidin-2-one. 11e (76% yield).
Table 2 In vitro inhibition of tubulin polymerization
Compound IC50 μM tubulin polymerization
11i 5.05 ± 1.2
CA-4 1.32 ± 0.2
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1H NMR (400 MHz, CDCl3): δ ppm 8.07 (sdd, 1 h, J = 1.8, 0.9
Hz), 7.53 (dd, 1H, J = 3.5, 0.9 Hz), 7.92 and 7.91 (AA′ system,
2H, J = 7.3 Hz), 6.90 (s, 1H), 6.79 (dd, 1H, J = 3.5, 1.7 Hz), 6.61
(s, 2H), 5.10 (s, 1H), 4.72 (s, 1H), 3.87 (s, CH3), 3.72 (s, CH3),
3.70 (s, 2× CH3). 13C (300 MHz, CDCl3): δ ppm 165.52, 163.7,
153.91, 153.89, 147.87, 147.02, 146.41, 144.36, 135.02, 133.98,
129.76, 122.15, 118.89, 112.92, 111.83, 109.12, 95.76, 66.11,
63.92, 61.53, 56.59, 56.51. MS (ESI): m/z 491 (M + Na).
10e. MS (ESI): m/z 585 (M + Na).
N-(2-Naphthoyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11f
(60% yield). 1H NMR (400 MHz, CDCl3): δ ppm 8.39 (s, 1H),
8.08 (d, 1H, J = 5.9 Hz, NH), 7.90–7.82 (4H), 7.55 (t, 1H, J =
7.4 Hz), 7.50 (t, 1H, J = 7.4 Hz), 6.97 (s, 1H), 6.89 (d, 1H, J =
7.5 Hz), 6.81 (d, 1H, J = 7.5 Hz), 6.52 (s, 2H), 5.04 (s, 1H),
4.93 (d, 1H, J = 5.9 Hz), 3.85 (s, 3H), 3.73 (s, 3H), 3.65 (s, 6H).
13C (400 MHz, CDCl3): 168.28, 165.35, 153.98, 147.81, 147.02,
135.58, 135.08, 134.17, 133.15, 130.69, 130.00, 129.79, 129.07,
128.94, 128.58, 128.34, 127.40, 124.25, 118.96, 113.02, 111.79,
95.81, 95.69, 66.87, 63.82, 61.59, 56.63, 56.59, 56.56. MS (ESI):
m/z 551 (M + Na).
10f. MS (ESI): m/z 705 (M + Na).
N-(Indolo-3-acetyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11g
(75% yield). 1H NMR (400 MHz, CDCl3): δ ppm 7.60 (d, 1H, J
= 7.34 Hz), 7.41 (d, 1H, J = 7.34 Hz), 7.28 (S, 1H), 7.26 (t, 1H,
J = 7.34 Hz), 7.21 (t, 1H, J = 7.34 Hz), 7.16 (s, 1H, NH), 6.89
(s, 1H), 6.83 (s, 2H), 6.51 (s, 2H), 6.37 (d, 1H, J = 6.13 Hz,
NH), 4.86 (s, 1H), 4.51 (d, 1H, J = 6.13 Hz), 3.89 (s, 3H), 3.80
(s, 2H), 3.76 (s, 3H), 3.69 (s, 6H). 13C (400 MHz, CDCl3):
172.69, 164.67, 154.07, 147.61, 146.69, 137.08, 135.3, 134.10,
130.12, 127.57, 123.44, 120.96, 119.24, 118.80, 112.87, 112.72,
112.27, 111.72, 108.87, 95.93, 66.60, 63.50, 61.58, 56.74,
56.70, 33.90. MS (ESI): m/z 554 (M + Na).
10g. MS (ESI): m/z 711 (M + Na).
N-(Cyclohexanoyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxy-
phenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11h
(69% yield). 1H NMR (400 MHz, CDCl3): δ ppm 6.92 (d, 1H, J
= 6.7 Hz, NH), 6.88 (s, 1 H), 6.83 (d, 1H, J = 8.4 Hz), 6.80 (d,
1H, J = 8.4 Hz), 6.44 (s, 2H), 4.87 (d, 1H, J = 1.5 Hz) 4.54 (dd,
1H, J = 6.7, 1.5 Hz), 3.84 (s, 3H), 3.76 (s, 3H), 3.66 (s, 6H),
2.15 (m, 1H), 1.86 (m, 2H), 1.75 (m, 2H), 1.64 (m, 2H), 1.43
(m, 2H), 1.25 (m, 2H). 13C (400 MHz, CDCl3): 177.63, 165.29,
153.98, 147,85, 147.02, 135.06, 134.20, 130.06, 118.87, 113.04,
111.84, 95.83, 66.41, 63.79, 61.53, 56.74, 56.68, 56.61, 45.44,
41.17, 30.06, 26.29, 26.24. MS (ESI): m/z 507 (M + Na).
11h. MS (ESI): m/z 617 (M + Na).
N-(Acetyl)-3,4-trans-3-amino-1-(3,4,5-trimethoxyphenyl)-4-
(3-hydroxy-4-methoxyphenyl)-azetidin-2-one. 11i (80% yield).
1H NMR (400 MHz, CDCl3): δ ppm 6.95 (s, 1H), 6.89 and 6.87
(AB system, 2H, J = 7.4 Hz), 6.55 (s, 2H), 6.33 (d, 1H, J = 7.5
Hz, NH), 4.91 (d, 1H, J = 1.5 Hz), 4.62 (dd, 1H, J = 7.4, 1.5
Hz), 3.91 (s, 3H), 3.86 (s, 3H), 3.72 (s, 6H), 2.10 (s, 3H). 13C
(400 MHz, CDCl3): 171.52, 165.24, 153.95, 153.93, 147.83,
147.02, 134.89, 134.18, 129.88, 118.79, 112.98, 111.80, 95.74,
66.18, 63.80, 61.57, 56.61, 23.36. MS (ESI): m/z: 439 (M + Na).
N-(S-2-amino-propanoyl)-3,4-trans-3-amino-1-(3,4,5-tri-
methoxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-azetidin-2-
one. 11j (80% yield). 1H NMR (300 MHz, CDCl3/CD3OD): δ
ppm 8.26 (bs, 2H), 6.91 (s, 1H), 6.84 and 6.79 (AB system,
2H, J = 8.2 Hz), 6.52 (s, 2H), 4.92 (s, 1H), 4.59 (s, 1H), 3.84 (s,
3H), 3.75 (s, 3H), 3.66 (s, 6H), 3.65 (m, 1H), 1.35 (d, 3H, J =
7.5 Hz). 13C (300 MHz, CDCl3/CD3OD): 170.01, 168.29,
154.07, 147.79, 147.10, 135.31, 134.18, 130.32, 118.43, 112.94,
111.80, 96.06, 95.86, 69.87, 66.89, 61.54, 56.67, 56.64, 51.17,
49.99, 20.60. MS (ESI): m/z 446 (M + 1).
N-Boc-11j. 1H NMR (300 MHz, CDCl3/CD3OD): 7.64 (s, 1H),
6.88 (s, 1H9), 6.88 and 6.86 (AB system, 2H, J = 7.4 Hz), 6.57
(s, 2H), 4.95 (s, 1H), 4.59 (s, 1H), 3.86 (s, 3H), 3.72 (s, 3H),
3.70 (s, 6H), 3.6 (q, 1H, J = 7.4 Hz), 1.45 (s, 9H), 1.34 (d, 3H, J
= 7.4 Hz). MS (ESI): m/z 568 (M + Na).
Biology
Reagents. RPMI-1640 medium, fetal bovine serum (FBS),
L-glutamine, penicillin, and streptomycin were obtained
from Lonza (Basel, Switzerland). All other reagents were
purchased from Sigma-Aldrich (St. Louis, MO).
Cell cultures. Colorectal adenocarcinoma SW48 cells were
purchased from ATCC, were cultured using RPMI-1640 me-
dium supplemented with 10% (v/v) FBS, 2 mM L-glutamine,
100 U mL−1 penicillin, and 100 μg mL−1 streptomycin and
were maintained at 37 °C in a humidified 5% CO2 incubator.
Growth inhibition assay. The antiproliferative activity of
the azetidinone derivatives was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. 8000 cells were seeded in 96-well plates and treated
with different concentrations of each compound (dissolved
in DMSO). After 72 h, the MTT solution was added and then
plates were incubated for 2 h at 37 °C. The purple formazan
crystals were solubilized and the plates were read on a Model
550 microplate reader (BioRad Laboratories, Hercules, CA) at
570 nm. Assays were performed in triplicate in three indepen-
dent experiments and data were analyzed using Sigma Plot
software (using the four parameter logistic equation) to esti-
mate IC50 values, defined as the concentration of drug caus-
ing 50% inhibition in absorbance compared to control cells
(in which 0.1% DMSO was used).
Tubulin polymerization assay. The effect of compounds
on tubulin polymerization was determined spectrophotomet-
rically, essentially as previously described.24 Lyophilized puri-
fied porcine brain tubulin (Cytoskeleton, Denver, CO) was
resuspended in assembly buffer (80 mM PIPES, pH 6.9, 1
mM MgCl2, 2 mM EGTA, 10% glycerol) at 2.5 mg mL−1 and
mixed with 1 mM GTP and varying concentrations of the in-
dicated compounds. DMSO (0.2% v/v) was used as a vehicle
control. Tubulin assembly was monitored at 340 nm at 37 °C
for 15 minutes on a Jasco V-530 spectrophotometer (Jasco Eu-
rope, Italy). The IC50 values are the compound concentrations
required to inhibit tubulin polymerization by 50% and were
estimated using the Sigma Plot software (using the four pa-
rameter logistic equation).
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